Akebia Therapeutics, Inc.

NASDAQ:AKBA

Biotechnology

Healthcare
$0.41 +0.49%

+$0.01 today

Market cap
$113.54M
Beta
0.25
P/E (TTM)
-13.3
EPS (TTM)
-$0.08
52W Low $0.82High $4.08

Volume 7.09M

Average 4.03M

AKBA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Akebia Therapeutics, Inc.NASDAQ: AKBA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns negative

Q1 FY2026 net income was -$9.05M, compared with $6.11M a year earlier. Trailing-twelve-month net income was -$20.51M. Over 3 fiscal years it compounded at -61.3% a year.

Context

  • Net income amounted to 2.3% of revenue in FY2025, down 41.1 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$48.43M (+806.1%) for the fiscal year ending Dec 2026, a step up from the -92.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$9.05M-26.1% QoQ
Last fiscal yearDec 2025
-$5.35M-92.3% YoY
LTMMar 2026
-$20.51M-54.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-248.1%-3603.5%-3355.3 pp
1 year-92.3%+806.1%+898.4 pp
3-year CAGR-61.3%+124.5%+185.8 pp
5-year CAGR+40.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(5.35M) USD
Year-over-year change
+92.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How AKBA compares with its peers on the latest reported figures

  • AKBA's LTM Mar 2026 net income of $20.51M is the smallest of the 10 companies compared; the peer median is $138.44M.
  • Its year-over-year change of -54.7% is the lowest of 9, against a peer median of +40.4%.
  • Net income amounts to 8.8% of revenue for AKBA, versus a peer median of 151.9%.
AKBA Competitors Peer median
Net Income for AKBA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$364.23M +879.7%—121.5%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$185.15M +43.6%+15.7%—
GOSSGossamer Bio, Inc.LTM Mar 2026$180.4M +252.1%-9.4%324.8%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$160.9M -8.8%+9.2%182.3%
PRTAProthena Corporation plcLTM Mar 2026$151.18M +37.1%+27.8%260.9%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$138.44M ——119.4%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$122.65M +233.3%—100.3%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$68.17M +23.5%+19.2%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$44.17M +6.7%-28.2%—
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$20.51M -54.7%-61.3%8.8%
Peer median (excluding AKBA) $138.44M+40.4%+12.5%151.9%

Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(282.02M)(92.56M)(51.93M)(69.41M)(5.35M)
Depreciation & Amortization36.13M37.7M41.85M37.5M1.27M
Deferred Income Tax00000
Stock-Based Compensation22.74M17.85M9.32M7.78M11.28M
Change in Working Capital(105.61M)(1.44M)(20.73M)(39.68M)16.47M
Accounts Receivables(24.03M)11.7M994K4.05M(14.14M)
Inventory(24.95M)19.79M(2.54M)(28.4M)(23.13M)
Accounts Payables(11.74M)1.5M(5.24M)(1.36M)3.08M
Other Working Capital(44.9M)(34.42M)(13.94M)(13.96M)50.66M
Other Non-Cash Items98.54M(34.7M)(1.9M)23.15M44.31M
Operating Cash Flow(252.97M)(73.15M)(23.38M)(40.66M)67.99M
Capital Expenditures(59K)(114K)0(33K)(291K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments40M0000
Other Investing Activities0000(7.93M)
Investing Cash Flow39.94M(114K)0(33K)(7.93M)
Debt Repayment44.78M(33M)(32M)7.9M4.63M
Common Stock Issued88.95M7.53M6.79M42.65M68.36M
Common Stock Repurchased000(1.27M)0
Dividends Paid00000
Other Financing Activities040.07M1K385K(63K)
Financing Cash Flow133.73M14.6M(25.21M)49.66M72.93M
Effect of Forex Changes00000
Net Change in Cash(79.29M)(58.67M)(48.59M)8.97M132.99M
Free Cash Flow(253.02M)(73.27M)(23.38M)(40.69M)67.99M

Akebia Therapeutics, Inc.

NASDAQ:AKBA

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.